491 / 1084
Oesophageal Cancer
„Standard Therapy“
• Phase II
88 patients
Stage IV
R
A
N
D
Cisplatin 100 mg/gm d1
5-FU 1000 mg/gm d1-5
O
M
Cisplatin 100 mg/gm d1
Bleiberg et al.
Eur J Cancer
1997; 33: 1216-20
n Pat.
Response rate
Median
survival
CDDP/5-FU
44
35%
33 weeks
CDDP mono
44
19%
28 weeks